<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151393">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01945489</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-OAB-113</org_study_id>
    <nct_id>NCT01945489</nct_id>
  </id_info>
  <brief_title>OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder</brief_title>
  <acronym>COMFORT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared
      with placebo, in achieving a 100% reduction in urinary incontinence in patients with
      overactive bladder (OAB) not properly managed with an anticholinergic.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants who Achieve a 100% Reduction in Urinary Incontinence Episodes</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Number of Episodes of Urinary Incontinence</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>King's Health Questionnaire (KHQ) domain scores</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Micturition Episodes</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Daily Urgency Episodes</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Nocturia Episodes</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/OnabotulinumtoxinA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>onabotulinumtoxinA</intervention_name>
    <description>OnabotulinumtoxinA (BOTOX®) injected into the detrusor.</description>
    <arm_group_label>OnabotulinumtoxinA</arm_group_label>
    <arm_group_label>Placebo/OnabotulinumtoxinA</arm_group_label>
    <other_name>BOTOX®</other_name>
    <other_name>botulinum toxin Type A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline (placebo) injected into the detrusor.</description>
    <arm_group_label>Placebo/OnabotulinumtoxinA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients with symptoms of Overactive Bladder (OAB) (frequency and urgency) with urinary
        incontinence for at least 6 months prior to screening.

        Exclusion Criteria:

          -  Symptoms of OAB due to a neurological reason

          -  Use of anticholinergics or other medications or therapies to treat symptoms of OAB
             within 7 days of screening

          -  Use of Clean Intermittent Catheterization (CIC) or indwelling catheter to manage
             urinary incontinence

          -  Use of botulinum toxin therapy of any serotype for any urological condition

          -  Use of botulinum toxin therapy of any serotype for any non-urological condition in
             the 12 weeks prior to screening

          -  History of any pelvic or urological abnormalities, bladder surgery or disease, other
             than OAB, that may affect bladder function

          -  Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, or Amyotrophic Lateral
             Sclerosis.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Mountlake Terrace</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>September 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
